Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Motohiro Tamiya

Showing results (71-80 of 192) with videos related to

Pageof 20
Sort By:
Investigational New Drugs|June 28, 2018
Proliferative CD8(+) PD-1(+) T-cell infiltration in a pembrolizumab-induced cutaneous adverse reactionKei Kunimasa, Taiki Isei, Harumi Nakamura, et al.
Anticancer Research|October 7, 2017
Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with NivolumabYoshihiko Taniguchi, Akihiro Tamiya, Syun-Ichi Isa, et al.
Clinical Lung Cancer|February 27, 2024
Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic CarcinomasYusuke Okuma, Shogo Nomura, Jun Sakakibara-Konishi, et al.
Scientific Reports|December 5, 2019
Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancerKeiko Nakao, Shinji Kobuchi, Shuhei Marutani, et al.
Cancer Science|February 9, 2024
Potent CTLs can be induced against tumor cells in an environment of lower levels of systemic MFG-E8Yu Mizote, Takako Inoue, Takashi Akazawa, et al.
JTO Clinical and Research Reports|November 8, 2021
Conversion Surgery for Advanced Thoracic SMARCA4-Deficient Undifferentiated Tumor With Atezolizumab in Combination With Bevacizumab, Paclitaxel, and Carboplatin Treatment: A Case ReportKei Kunimasa, Jiro Okami, Satoshi Takenaka, et al.
Investigational New Drugs|May 20, 2020
Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trialKazuhisa Nakashima, Yuichi Ozawa, Haruko Daga, et al.
Translational Lung Cancer Research|May 20, 2021
Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective studyKinnosuke Matsumoto, Akihiro Tamiya, Yoshinobu Matsuda, et al.
Cancer Diagnosis & Prognosis|May 5, 2025
Relationship Between T790M Allele Frequency and Therapeutic Effects Before and After EGFR-TKI Administration Using Droplet Digital PCR in Non-small-cell Lung Cancer With EGFR MutationKoichi Ogawa, Hiroyasu Kaneda, Yasuhiro Koh, et al.
Journal of Geriatric Oncology|October 4, 2021
Efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non-small cell lung cancer: A multicenter retrospective cohort studyKinnosuke Matsumoto, Akihiro Tamiya, Yuji Inagaki, et al.
Pageof 20

Showing results (71-80 of 192) with videos related to

Sort By:
Pageof 20
Investigational New Drugs|June 28, 2018
Proliferative CD8(+) PD-1(+) T-cell infiltration in a pembrolizumab-induced cutaneous adverse reactionKei Kunimasa, Taiki Isei, Harumi Nakamura, et al.
Anticancer Research|October 7, 2017
Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with NivolumabYoshihiko Taniguchi, Akihiro Tamiya, Syun-Ichi Isa, et al.
Clinical Lung Cancer|February 27, 2024
Artemis: A Multicenter, Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of First-Line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic CarcinomasYusuke Okuma, Shogo Nomura, Jun Sakakibara-Konishi, et al.
Scientific Reports|December 5, 2019
Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancerKeiko Nakao, Shinji Kobuchi, Shuhei Marutani, et al.
Cancer Science|February 9, 2024
Potent CTLs can be induced against tumor cells in an environment of lower levels of systemic MFG-E8Yu Mizote, Takako Inoue, Takashi Akazawa, et al.
JTO Clinical and Research Reports|November 8, 2021
Conversion Surgery for Advanced Thoracic SMARCA4-Deficient Undifferentiated Tumor With Atezolizumab in Combination With Bevacizumab, Paclitaxel, and Carboplatin Treatment: A Case ReportKei Kunimasa, Jiro Okami, Satoshi Takenaka, et al.
Investigational New Drugs|May 20, 2020
Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trialKazuhisa Nakashima, Yuichi Ozawa, Haruko Daga, et al.
Translational Lung Cancer Research|May 20, 2021
Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective studyKinnosuke Matsumoto, Akihiro Tamiya, Yoshinobu Matsuda, et al.
Cancer Diagnosis & Prognosis|May 5, 2025
Relationship Between T790M Allele Frequency and Therapeutic Effects Before and After EGFR-TKI Administration Using Droplet Digital PCR in Non-small-cell Lung Cancer With EGFR MutationKoichi Ogawa, Hiroyasu Kaneda, Yasuhiro Koh, et al.
Journal of Geriatric Oncology|October 4, 2021
Efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non-small cell lung cancer: A multicenter retrospective cohort studyKinnosuke Matsumoto, Akihiro Tamiya, Yuji Inagaki, et al.
Pageof 20